Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: Role of plasticity and heterogeneity

Massimo Conese, Donatella Piro, Annalucia Carbone, Stefano Castellani, Sante Di Gioia

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Chronic lung diseases, such as cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD) are incurable and represent a very high social burden. Stem cell-based treatment may represent a hope for the cure of these diseases. In this paper, we revise the overall knowledge about the plasticity and engraftment of exogenous marrow-derived stem cells into the lung, as well as their usefulness in lung repair and therapy of chronic lung diseases. The lung is easily accessible and the pathophysiology of these diseases is characterized by injury, inflammation, and eventually by remodeling of the airways. Bone marrow-derived stem cells, including hematopoietic stem/progenitor cells (HSPCs) and mesenchymal stromal (stem) cells (MSCs), encompass a wide array of cell subsets with different capacities of engraftment and injured tissue regenerating potential. Proof-of-principle that marrow cells administered locally may engraft and give rise to specialized epithelial cells has been given, but the efficiency of this conversion is too limited to give a therapeutic effect. Besides the identification of plasticity mechanisms, the characterization/isolation of the stem cell subpopulations represents a major challenge to improving the efficacy of transplantation protocols used in regenerative medicine for lung diseases.

Original languageEnglish
Article number859817
JournalTheScientificWorldJournal
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Pulmonary diseases
respiratory disease
Hematopoietic Stem Cells
Stem cells
Mesenchymal Stromal Cells
Plasticity
plasticity
Chronic Disease
Stem Cells
stem
Lung Diseases
Bone Marrow
Lung
Airway Remodeling
Regenerative Medicine
Therapeutic Uses
Cystic Fibrosis
Chronic Obstructive Pulmonary Disease
transplantation
asthma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)
  • Medicine(all)

Cite this

Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases : Role of plasticity and heterogeneity. / Conese, Massimo; Piro, Donatella; Carbone, Annalucia; Castellani, Stefano; Di Gioia, Sante.

In: TheScientificWorldJournal, Vol. 2014, 859817, 2014.

Research output: Contribution to journalArticle

@article{301e112fee0c4fd6b4b540ce40a6df3b,
title = "Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: Role of plasticity and heterogeneity",
abstract = "Chronic lung diseases, such as cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD) are incurable and represent a very high social burden. Stem cell-based treatment may represent a hope for the cure of these diseases. In this paper, we revise the overall knowledge about the plasticity and engraftment of exogenous marrow-derived stem cells into the lung, as well as their usefulness in lung repair and therapy of chronic lung diseases. The lung is easily accessible and the pathophysiology of these diseases is characterized by injury, inflammation, and eventually by remodeling of the airways. Bone marrow-derived stem cells, including hematopoietic stem/progenitor cells (HSPCs) and mesenchymal stromal (stem) cells (MSCs), encompass a wide array of cell subsets with different capacities of engraftment and injured tissue regenerating potential. Proof-of-principle that marrow cells administered locally may engraft and give rise to specialized epithelial cells has been given, but the efficiency of this conversion is too limited to give a therapeutic effect. Besides the identification of plasticity mechanisms, the characterization/isolation of the stem cell subpopulations represents a major challenge to improving the efficacy of transplantation protocols used in regenerative medicine for lung diseases.",
author = "Massimo Conese and Donatella Piro and Annalucia Carbone and Stefano Castellani and {Di Gioia}, Sante",
year = "2014",
doi = "10.1155/2014/859817",
language = "English",
volume = "2014",
journal = "The Scientific World Journal",
issn = "2356-6140",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases

T2 - Role of plasticity and heterogeneity

AU - Conese, Massimo

AU - Piro, Donatella

AU - Carbone, Annalucia

AU - Castellani, Stefano

AU - Di Gioia, Sante

PY - 2014

Y1 - 2014

N2 - Chronic lung diseases, such as cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD) are incurable and represent a very high social burden. Stem cell-based treatment may represent a hope for the cure of these diseases. In this paper, we revise the overall knowledge about the plasticity and engraftment of exogenous marrow-derived stem cells into the lung, as well as their usefulness in lung repair and therapy of chronic lung diseases. The lung is easily accessible and the pathophysiology of these diseases is characterized by injury, inflammation, and eventually by remodeling of the airways. Bone marrow-derived stem cells, including hematopoietic stem/progenitor cells (HSPCs) and mesenchymal stromal (stem) cells (MSCs), encompass a wide array of cell subsets with different capacities of engraftment and injured tissue regenerating potential. Proof-of-principle that marrow cells administered locally may engraft and give rise to specialized epithelial cells has been given, but the efficiency of this conversion is too limited to give a therapeutic effect. Besides the identification of plasticity mechanisms, the characterization/isolation of the stem cell subpopulations represents a major challenge to improving the efficacy of transplantation protocols used in regenerative medicine for lung diseases.

AB - Chronic lung diseases, such as cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD) are incurable and represent a very high social burden. Stem cell-based treatment may represent a hope for the cure of these diseases. In this paper, we revise the overall knowledge about the plasticity and engraftment of exogenous marrow-derived stem cells into the lung, as well as their usefulness in lung repair and therapy of chronic lung diseases. The lung is easily accessible and the pathophysiology of these diseases is characterized by injury, inflammation, and eventually by remodeling of the airways. Bone marrow-derived stem cells, including hematopoietic stem/progenitor cells (HSPCs) and mesenchymal stromal (stem) cells (MSCs), encompass a wide array of cell subsets with different capacities of engraftment and injured tissue regenerating potential. Proof-of-principle that marrow cells administered locally may engraft and give rise to specialized epithelial cells has been given, but the efficiency of this conversion is too limited to give a therapeutic effect. Besides the identification of plasticity mechanisms, the characterization/isolation of the stem cell subpopulations represents a major challenge to improving the efficacy of transplantation protocols used in regenerative medicine for lung diseases.

UR - http://www.scopus.com/inward/record.url?scp=84893825139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893825139&partnerID=8YFLogxK

U2 - 10.1155/2014/859817

DO - 10.1155/2014/859817

M3 - Article

C2 - 24563632

AN - SCOPUS:84893825139

VL - 2014

JO - The Scientific World Journal

JF - The Scientific World Journal

SN - 2356-6140

M1 - 859817

ER -